These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 34269290

  • 41. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study.
    Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A.
    PLoS One; 2021; 16(5):e0249426. PubMed ID: 33961627
    [Abstract] [Full Text] [Related]

  • 42. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang X, Wang K, Wang M, Yang G, Ye X, Wu M, Cheng S.
    Oncotarget; 2017 Apr 25; 8(17):29416-29427. PubMed ID: 28177886
    [Abstract] [Full Text] [Related]

  • 43. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease.
    Choi HS, Kang KM, Jeong BK, Jeong H, Lee YH, Ha IB, Song JH.
    Asia Pac J Clin Oncol; 2021 Jun 25; 17(3):209-215. PubMed ID: 32757461
    [Abstract] [Full Text] [Related]

  • 44. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
    Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS.
    J Vasc Interv Radiol; 2015 Mar 25; 26(3):320-9.e6. PubMed ID: 25612807
    [Abstract] [Full Text] [Related]

  • 45. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
    Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, Zhang YJ, Meng Y, Yang YF, Cong WM, Wu MC, Lau WY, Cheng SQ.
    Medicine (Baltimore); 2016 Mar 25; 95(11):e3015. PubMed ID: 26986115
    [Abstract] [Full Text] [Related]

  • 46. Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study.
    Ou X, Wu J, Wu J, Fu Y, Zeng Z, Li S, Li Y, Liu D, Li H, Li B, Zhou J, Zhuang S, Cheng S, Zhang Z, Wang K, Qu S, Yan M.
    Cancer Res Treat; 2024 Oct 25; 56(4):1207-1218. PubMed ID: 38697847
    [Abstract] [Full Text] [Related]

  • 47. Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang XP, Wang K, Li N, Zhong CQ, Wei XB, Cheng YQ, Gao YZ, Wang H, Cheng SQ.
    BMC Cancer; 2017 Dec 28; 17(1):902. PubMed ID: 29282010
    [Abstract] [Full Text] [Related]

  • 48. Experience With LDLT in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Postdownstaging.
    Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, Gautam D, Choudhary NS, Thiagarajan S, Rastogi A, Saraf N, Saigal S.
    Transplantation; 2020 Nov 28; 104(11):2334-2345. PubMed ID: 32032291
    [Abstract] [Full Text] [Related]

  • 49. Therapeutic value of transcatheter arterial chemoembolization combined with portal vein embolization for primary hepatocellular carcinoma with portal vein tumor thrombus: a pilot study.
    Tan X, Xie P, Liu J, Wu H, Xie Y.
    Asia Pac J Clin Oncol; 2015 Sep 28; 11(3):e6-e12. PubMed ID: 25228074
    [Abstract] [Full Text] [Related]

  • 50. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.
    Li L, Cheng N, Huang X, Weng X, Jiao Y, Liu J, Guo W.
    World J Surg Oncol; 2022 Feb 02; 20(1):30. PubMed ID: 35109883
    [Abstract] [Full Text] [Related]

  • 51. Combined transcatheter arterial chemoembolization and radiofrequency ablation in single-session for solitary hepatocellular carcinoma larger than 7 cm.
    Yan JY, Zhang JL, Wang MQ, Yuan K, Bai YH, Wang Y, Xin HN, Wang ZJ, Liu FY, Duan F, Fu JX.
    Asia Pac J Clin Oncol; 2018 Aug 02; 14(4):300-309. PubMed ID: 29124894
    [Abstract] [Full Text] [Related]

  • 52. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Yamamoto Y, Ikoma H, Morimura R, Shoda K, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Kubota T, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C, Ochiai T, Otsuji E.
    World J Gastroenterol; 2015 Jan 07; 21(1):246-53. PubMed ID: 25574098
    [Abstract] [Full Text] [Related]

  • 53. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
    Zhang L, Sun JH, Hou ZH, Zhong BY, Yang MJ, Zhou GH, Wang WS, Huang P, Zhang S, Li Z, Zhu XL, Yan ZP, Ni CF.
    Cardiovasc Intervent Radiol; 2021 Jan 07; 44(1):63-72. PubMed ID: 32965582
    [Abstract] [Full Text] [Related]

  • 54. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
    Zhang Y, Miao H, Xie W, Jiang S, Song Z, Huang G, Fan W, Wang Y, Li J, Chen Y.
    Eur Radiol; 2021 Jan 07; 31(1):232-243. PubMed ID: 32728770
    [Abstract] [Full Text] [Related]

  • 55. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation.
    Zhou Q, An Y, Liu T, Liu Z, Li R, Wang C, Zhou F, Liu C, Zhu K.
    Int J Hyperthermia; 2022 Jan 07; 39(1):97-107. PubMed ID: 34979845
    [Abstract] [Full Text] [Related]

  • 56. Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification.
    Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, Li ZK, Qi F, Zhao C.
    Med Oncol; 2012 Dec 07; 29(4):2992-7. PubMed ID: 22200992
    [Abstract] [Full Text] [Related]

  • 57. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation.
    Yang Z, Zou R, Zheng Y, Qiu J, Shen J, Liao Y, Zhang Y, Wang C, Wang Y, Yuan Y, Li K, Zuo D, He W, Liu W, Li B, Yuan Y.
    Eur Radiol; 2019 Nov 07; 29(11):5752-5762. PubMed ID: 30993438
    [Abstract] [Full Text] [Related]

  • 58. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX, Gan YH, Ge NL, Chen Y, Ma H, Wang Y, Zhang BH, Wang YH, Ye SL, Luo JF, Ren ZG.
    J Gastroenterol Hepatol; 2016 Feb 07; 31(2):442-9. PubMed ID: 26259976
    [Abstract] [Full Text] [Related]

  • 59. Safety and Efficacy of Irradiation Stent Placement for Malignant Portal Vein Thrombus Combined with Transarterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center Experience.
    Lu J, Guo JH, Zhu HD, Zhu GY, Chen L, Teng GJ.
    J Vasc Interv Radiol; 2017 Jun 07; 28(6):786-794.e3. PubMed ID: 28396192
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.